A phase II trial of gemcitabine in a fixed dose rate infusion combined with cisplatin in patients with operable biliary tract carcinomas

A phase II trial of gemcitabine in a fixed dose rate infusion combined with cisplatin in patients with operable biliary tract carcinomas with the primary objective tumour response

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000001695

Acronym

ABC trial

Enrollment

Registered

2005-07-07

Start date

2005-02-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Gemcitabine delivered as fixed dose-rate infusion with cisplatin

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

0 to No maximum

Healthy volunteers

Inclusion criteria

Histologic or cytologic diagnosis of adenocarcinogen of the gallbladder or intra/extrahepatic bile ducts with locally advanced or metastatic disease that is not amenable to curative surgical resection or with recurrent disease after prior surgical resection or radiotherapy. Measurable disease.

Exclusion criteria

No exclusion criteria

Outcome results